8 April 2008

2 minute read

North America

AspenBio licensed this single-chain technology from Washington University in St. Louis for use in all animal species. The technology was developed over the past 15 years by Dr. Irving Boime, a Department of Developmental Biology professor at Washington University's School of Medicine.

BoviPure FSH is a novel single chain follicle stimulating hormone (FSH) analog for cows with many potential advantages over existing products. The makers claim this new bovine LH hormone analog is the first of its type in the world and is designed to increase pregnancy rates in dairy cows using both pre-breeding and post-breeding applications.

"The execution of this agreement successfully culminates an important 2008 objective for AspenBio Pharma," said Richard Donnelly, AspenBio's president and CEO. "In addition to securing very attractive and what we believe to be highly competitive royalty terms, having Novartis as a partner means these drugs will be launched by an organization with leading market positions in the most important countries throughout the world. Novartis also has a large worldwide sales and marketing team with a strong track record of success in launching new drugs."

Boime, whose team worked to develop the platform technology, commented, "I am delighted to see that basic science research conducted here at Washington University has generated a therapeutic class of veterinary drugs to help improve the success of livestock reproduction."

AspenBio Pharma is an emerging bio-pharmaceutical company dedicated to the discovery; development, manufacture, and marketing of novel proprietary products, including those that enhance the reproductive efficiency of animals and that have large worldwide market potential.

TheCattleSite News Desk